Almost 25 years ago, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was licensed for the treatment of patients with metastatic HER2-positive breast cancer in the United States of America (USA) [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341063 | PMC |
| http://dx.doi.org/10.3390/cancers15133333 | DOI Listing |
Publication Analysis
Top Keywords
her-2-positive tumors
4
tumors continuously
4
continuously evolving
4
evolving field
4
field cancer
4
cancer years
4
years ago
4
ago trastuzumab
4
trastuzumab monoclonal
4
monoclonal antibody
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!